PUNE, INDIA (REUTERS) - Novavax Inc and its partner Serum Institute of India have applied to the World Health Organisation for an emergency use listing of Novavax's Covid-19 vaccine, the company said on Thursday (Sept 23).
The WHO's emergency use listing is a signal to national regulatory authorities of a product's safety and efficacy.
It is also a prerequisite for exportation to several countries participating in the Covax vaccine sharing facility.
Novavax and Serum Institute, the world's largest vaccine producer, have committed to together provide more than 1.1 billion doses to the Covax facility, which aims to provide equitable access to Covid-19 vaccines to low- and middle-income countries.
The Novavax shot is a protein-based vaccine, and has shown 90.4 per cent efficacy overall in trials in the United States and Mexico.
Related Story
Novavax delays seeking US approval for Covid-19 vaccine, prioritising nations more in need
Related Story
Novavax says Taiwan has opted to get firm's Covid-19 vaccine via Covax sharing scheme
Related Stories:
Related Story
Testing positive for Covid-19: Where do you seek help and what kind of treatment do you need?
Related Story
Chinese city Harbin orders spas, mahjong salons to shut after Covid-19 case confirmed
Related Story
Thailand okays injecting Covid-19 vaccine under skin instead of in muscle to stretch supplies
Related Story
Bats in Laos caves found to carry coronaviruses that share key feature with Sars-CoV-2
Related Story
Thousands of Covid-like infections show risk of next pandemic: Study
Related Story
Governments face tough call on risky reopenings as Covid-19 persists
Related Story
Let us buy Covid-19 vaccines, pleads Africa
Related Story
When Covid-19 stole their sense of smell, these experts lost their careers
Related Story
Britain and neighbours set out paths for coping with Covid-19
Related Story
'My saviour': Hanoi's tiny balconies a refuge in Covid-19 lockdown
Join ST's Telegram channel here and get the latest breaking news delivered to you.
Topics:
More Whatsapp Linkedin FB Messenger Telegram Reddit WeChat Pinterest Print Copy permalink https://str.sg/3TUu